Saltar al contenido principal
xMedica

NCT05922878ClinicalTrials.gov

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Fase 2325 participantes buscados75 centros1 país

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 325 participants (target), run at 75 sites.

How this score is built
  • Enrolment24/40

    321 participants (target)

  • Site count19/25

    45 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 42 months

  • Sponsor scale2/10

    Alto Neuroscience has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Afecciones

  • Major Depressive Disorder

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – 70 Years
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 2
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción325 participantes buscados

Patrocinador y colaboradores

  • Alto Neuroscience Patrocinador

Grupos e intervenciones

  • ALTO-300EXPERIMENTAL

    Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.

Intervenciones

  • Fármaco ALTO-300

    ALTO-300 capsule QD

  • Fármaco Placebo

    Placebo capsule QD

Variables de resultado

  1. Variable de resultado principal

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Plazo Change over time for up to week 6

  2. Variable de resultado secundaria

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Plazo Change over time for up to week 6

  3. Variable de resultado secundaria

    To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Plazo Change over time for up to week 6

  4. Variable de resultado secundaria

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.

    Incidence, severity, and relatedness of Adverse Events

    Plazo Assessed from Day 1 to Week 14

  5. Variable de resultado secundaria

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.

    Assessment of Heart Rate

    Plazo Assessed from Day 1 to Week 14

  6. Variable de resultado secundaria

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.

    Assessment of Weight Change

    Plazo Assessed from Day 1 to Week 14

  7. Variable de resultado secundaria

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.

    Assessment of Blood Pressure

    Plazo Assessed from Day 1 to Week 14

  8. Variable de resultado secundaria

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).

    The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.

    Plazo Assessed from Day 1 to Week 15

Fechas

Fechas
Fecha de inicio8 de junio de 2023 (real)
Finalización principal1 de diciembre de 2026 (estimada)
Finalización1 de diciembre de 2026 (estimada)
Primera publicación28 de junio de 2023 (real)
Última actualización26 de octubre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezoctubre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

30 centros están en reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Site 114AlbuquerqueNew MexicoEn reclutamiento
Site 216AllentownPennsylvaniaFinalizado antes de tiempo
Site 316AustinTexasEn reclutamiento
Site 218BellflowerCaliforniaEn reclutamiento
Site 317BlackfootIdahoRetirado
Site 236BoiseIdahoEn reclutamiento
Site 119BoiseIdahoActivo, sin reclutar
Site 318CarlsbadCaliforniaActivo, sin reclutar
Site 310ChicagoIllinoisActivo, sin reclutar
Site 202CincinnatiOhioEn reclutamiento
Site 159ClermontFloridaFinalizado antes de tiempo
Site 207ClintonUtahActivo, sin reclutar
Site 203Colorado SpringsColoradoActivo, sin reclutar
Site 239ConroeTexasEn reclutamiento
Site 229Creve CouerMissouriRetirado
Site 102DallasTexasActivo, sin reclutar
Site 343DenverColoradoEn reclutamiento
Site 349EvergreenColoradoActivo, sin reclutar
Site 345EvergreenColoradoActivo, sin reclutar
Site 277FairfaxVirginiaEn reclutamiento
Site 238FayettevilleGeorgiaEn reclutamiento
Site 148Fort WorthTexasRetirado
Site 347Fort WorthTexasFinalizado antes de tiempo
Site 217GlendaleCaliforniaActivo, sin reclutar
Site 279HattiesburgMississippiRetirado
Site 199HickoryNorth CarolinaActivo, sin reclutar
Site 320HoustonTexasEn reclutamiento
Site 275HoustonTexasEn reclutamiento
Site 215JacksonMississippiActivo, sin reclutar
Site 335LafayetteCaliforniaEn reclutamiento
Site 335LafayetteCaliforniaEn reclutamiento
Site 344Las VegasNevadaEn reclutamiento
Site 209Los AngelesCaliforniaActivo, sin reclutar
Site 240MankatoMinnesotaEn reclutamiento
Site 201MarreroLouisianaFinalizado antes de tiempo
Site 219MatherCaliforniaEn reclutamiento
Site 350MediaPennsylvaniaRetirado
Site 225Miami GardensFloridaActivo, sin reclutar
Site 190Miami LakesFloridaActivo, sin reclutar
Site 265MinneapolisMinnesotaEn reclutamiento
Site 194Mission ViejoCaliforniaFinalizado antes de tiempo
Site 206Missouri CityTexasRetirado
Site 198MonroeLouisianaFinalizado antes de tiempo
Site 267MoorparkCaliforniaEn reclutamiento
Site 352MoosicPennsylvaniaActivo, sin reclutar
Site 283New YorkNew YorkEn reclutamiento
Site 319New YorkNew YorkActivo, sin reclutar
Site 214NorwalkConnecticutRetirado
Site 161OkeechobeeFloridaActivo, sin reclutar
Site 195Oklahoma CityOklahomaFinalizado antes de tiempo

En el registro figuran 25 centros más.

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 26 de octubre de 2026

    Objetivo de inscripción modificado

    Enrollment target revised up from 321 to 325

    321325

  2. 26 de octubre de 2026

    Centro añadido

    30 sites added (75 total)

    4575